EUCTR2007-004543-30-BE进行中（未招募）不适用
A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, 12-WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA - N/A
Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US0 个研究点目标入组 120 人开始时间: 2008年3月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Are male or female =18 years of age (neonates are required to be at least 36 weeks gestational age);
- •2. Have a diagnosis of paediatric glaucoma;
- •3. Require pharmacological intervention with IOP reducing therapy in at least 1 eye;
- •4. Have a morning (before mid day) baseline visit IOP =22 mmHg in at least 1 eye;
- •5. Are on topical therapy or are naïve to pharmacologic treatment;
- •6. Have signed and dated an informed consent document indicating that subject’s parent (or legal guardian) had been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws.
- •7. Are willing and able to comply with scheduled visits (parent or legal guardian).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Require surgery for acute angle closure or closed or a narrowly open anterior chamber angle;
- •2. Have failed previous long term therapeutic intervention with either timolol or a prostaglandin to control elevated IOP;
- •3. Have had prior cyclodestructive procedures;
- •4. Cannot expect reasonable improvement by pharmacologic treatment, which is given in addition to filtering surgeries (eg, trabeculectomy) or drainage implants (history of surgery or implant is not the condition of exclusion);
- •5. Have or have had other medical condition(s) in which treatment with beta blocking agents are contraindicated such as heart failure, sinus bradycardia, second and third degree atrio ventricular block, bronchial asthma or history thereof, and obstructive pulmonary disease;
- •6. Have ocular inflammation/infection or a history of ocular inflammation/infection within 3 months prior to the baseline visit;
- •7. Have a history of ocular trauma or surgery in either eye within 1 month of the baseline visit;
- •8. Have a history of allergy to any of the ingredients contained in the study medications (eg, hypersensitivity to benzalkonium chloride, or to any other component in Xalatan and or timolol);
- •9. Have any corneal condition that would prevent tonometric measurements;
- •10. Have, or have had a history of chronic allergic conjunctivitis, chronic keratitis or lacrimal deficiency;
- •11. Have taken systemic and/or ocular steroids within 1 month of the baseline visit (eg, prednisolone drops);
- •12. Anticipate the need to initiate or modify medication (systemic or topical) that is known to affect IOP during the study period;
- •13. Have, or have had a history of any other severe acute or chronic medical or psychiatric condition that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, could make the subject inappropriate for entry into this study;
- •14. Have used an investigational drug or device within 30 days of the baseline visit;
- •15. Is pregnant or nursing females; [menarchal females of child bearing potential (females age 10 or greater, or who are menarchal) must have a negative pregnancy test, and those who are unwilling or unable to follow the instruction to avoid pregnancy, from at least 14 days prior to the first dose of trial mediation until completion of follow up procedure, will not participate to the trial.] (proper methods to avoid pregnancy should be instructed at the entrance of the study).
研究者
相似试验
进行中（未招募）
不适用
A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, 12-WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA - N/AEUCTR2007-004543-30-SKPfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US120
进行中（未招募）
1 期
A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, 12-WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA - N/AMedDRA version: 9.1Level: LLTClassification code 10010486Term: Congenital glaucomaEUCTR2007-004543-30-SIPfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US120
进行中（未招募）
不适用
A Phase III , 12 week study of Xalatan (latanoprost) and Timoptol (timolol) in children with glaucomaThe study intends to attain the indication that Xalatan (latanoprost ophthalmic solution 0.005%) is suitable for the reduction of elevated intraocular pressure (IOP) in paediatric subjects (=18 years of age) with glaucoma.MedDRA version: 14.1Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010486Term: Congenital glaucomaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2007-004543-30-Outside-EU/EEAPfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US120
进行中（未招募）
不适用
A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, 12-WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA - N/AThe study intends to attain the indication that Xalatan (latanoprost ophthalmic solution 0.005%) is suitable for the reduction of elevated intraocular pressure (IOP) in paediatric subjects (=18 years of age) with glaucoma.MedDRA version: 9.1Level: LLTClassification code 10010486Term: Congenital glaucomaEUCTR2007-004543-30-DKPfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US120
进行中（未招募）
不适用
A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, 12-WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA - N/AThe study intends to attain the indication that Xalatan (latanoprost ophthalmic solution 0.005%) is suitable for the reduction of elevated intraocular pressure (IOP) in paediatric subjects (=18 years of age) with glaucoma.MedDRA version: 9.1Level: LLTClassification code 10010486Term: Congenital glaucomaEUCTR2007-004543-30-GRPfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US120